Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

Phase 3 Completed 187 enrolled Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC

NaSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.

Timeline

Start: 2015-10
Primary completion: 2017-06
Completion: 2017-06

Publications

Pahwa R, Molho E, Lew M, Dashtipour K, Gil RA, Revilla FJ, Clinch T, Qin P, Isaacson SH; OPen Label Trial of Intraglandular MYobloc injections for Sialorrhea Treatment (OPTIMYST) study group. Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial. Neurol Ther. 2025 Aug;14(4):1553-1567. doi: 10.1007/s40120-025-00777-z. Epub 2025 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum Toxin Type B	Unknown	3500 iu	Other

Indications

No indication recorded.